This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oda, T. Articles by Hirohashi, S. Search for Related Content PubMed PubMed Citation Articles by Oda, T. Articles by Hirohashi, S.

p53 Gene Mutation Spectrum in Hepatocellular Carcinoma¹

Pathology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104 [T. O., H. T., A. S., M. S., S. H.], and Institute of Clinical Medicine, Surgery, Tsukuba University, 1-1-1 Tennodai, Tsukuba city, Ibaraki 305 [T. O.], Japan

In order to clarify the significance of mutation of the p53 tumor suppressor gene in the genesis and development of human hepatocellular carcinoma (HCC) in an aflatoxin B₁ low-exposure area, the spectrum, i.e., incidence, type, and site, of p53 gene mutations was examined in 169 tissue samples resected mainly from Japanese patients using single-strand conformation polymorphism analysis and direct sequencing. Forty-nine tumors (29%) showed a p53 mutation (39 point mutations and 10 frameshifts). The point mutations comprised 18 transitions, only 4 of which occurred at CpG sites, and 21 transversions. Two evolutionarily conserved domains, IV and V, contained 65% of all mutations and codon 249 was the most frequent mutation site (7/49). The spectrum of p53 mutation did not differ among HCCs in relation to the type of hepatitis virus infection, sex, age, and background liver disease of patients, tumor size, or presence of metastasis, but incidence and site were significantly associated with the degree of differentiation of cancer cells. In poorly differentiated HCC, p53 mutation was frequent (54%) and clustered on domains IV and V, whereas in well or moderately differentiated HCC, the mutation was less frequent (21%) and equally distributed on domains II to V. Restriction fragment length polymorphism analysis revealed loss of heterozygosity on chromosome 17p in 55 (69%) of 80 informative cases and in 34 (95%) of 36 cases with p53 mutation. Therefore, p53 gene mutation is suggested to occur independently of the type of viral infection or status of preexisting liver disease and to occur preferentially in moderately and poorly differentiated HCCs in association with or after loss of another p53 allele as a late event of HCC progression.

¹ This study was supported by a Grant-in-Aid for the Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan.

² Awardee of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research, Tokyo, Japan.

³ Supported by a Foreign Research Fellowship. Present address: Institute of Pathology, Verona University, Strada Le Grazie, 37134 Verona, Italy.

⁴ To whom requests for reprints should be addressed.

Received 6/22/92. Accepted 9/11/92.

This article has been cited by other articles:

				M. K. Lee and K. Sabapathy The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo J. Cell Sci., June 1, 2008; 121(11): 1899 - 1906. [Abstract] [Full Text] [PDF]

				D. S. Wilkinson, W.-W. Tsai, M. A. Schumacher, and M. C. Barton Chromatin-Bound p53 Anchors Activated Smads and the mSin3A Corepressor To Confer Transforming Growth Factor {beta}-Mediated Transcription Repression Mol. Cell. Biol., March 15, 2008; 28(6): 1988 - 1998. [Abstract] [Full Text] [PDF]

				M. A. Jackson, I. Lea, A. Rashid, S. D. Peddada, and J. K. Dunnick Genetic Alterations in Cancer Knowledge System: Analysis of Gene Mutations in Mouse and Human Liver and Lung Tumors Toxicol. Sci., April 1, 2006; 90(2): 400 - 418. [Abstract] [Full Text] [PDF]

				M E Guicciardi and G J Gores Apoptosis: a mechanism of acute and chronic liver injury Gut, July 1, 2005; 54(7): 1024 - 1033. [Full Text] [PDF]

				C.P. Wild and P.C. Turner The toxicology of aflatoxins as a basis for public health decisions Mutagenesis, November 1, 2002; 17(6): 471 - 481. [Abstract] [Full Text] [PDF]

				M. C. Stern, D. M. Umbach, M. C. Yu, S. J. London, Z.-Q. Zhang, and J. A. Taylor Hepatitis B, Aflatoxin B1, and p53 Codon 249 Mutation in Hepatocellular Carcinomas from Guangxi, People's Republic of China, and a Meta-analysis of Existing Studies Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 617 - 625. [Abstract] [Full Text] [PDF]

				K.-S. Jeng, I-S. Sheen, B.-F. Chen, and J.-Y. Wu Is the p53 Gene Mutation of Prognostic Value in Hepatocellular Carcinoma After Resection? Arch Surg, November 1, 2000; 135(11): 1329 - 1333. [Abstract] [Full Text] [PDF]

				S. Kubicka, F. Kuhnel, L. Zender, K. L. Rudolph, J. Plumpe, M. Manns, and C. Trautwein p53 Represses CAAT Enhancer-binding Protein (C/EBP)-dependent Transcription of the Albumin Gene. A MOLECULAR MECHANISM INVOLVED IN VIRAL LIVER INFECTION WITH IMPLICATIONS FOR HEPATOCARCINOGENESIS J. Biol. Chem., November 5, 1999; 274(45): 32137 - 32144. [Abstract] [Full Text] [PDF]

				K. S. Iwamoto, S. Fujii, A. Kurata, M. Suzuki, T. Hayashi, Y. Ohtsuki, Y. Okada, M. Narita, M. Takahashi, S. Hosobe, et al. p53 mutations in tumor and non-tumor tissues of Thorotrast recipients: a model for cellular selection during radiation carcinogenesis in the liver Carcinogenesis, July 1, 1999; 20(7): 1283 - 1291. [Abstract] [Full Text] [PDF]